- SEK1.55bn
- SEK1.46bn
- SEK130.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 47.02 | ||
| PEG Ratio (f) | 20.08 | ||
| EPS Growth (f) | 2.4% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.8 | ||
| Price to Tang. Book | 7.06 | ||
| Price to Free Cashflow | 41.78 | ||
| Price to Sales | 11.89 | ||
| EV to EBITDA | 25.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.28% | ||
| Return on Equity | 15.72% | ||
| Operating Margin | 35.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 61.03 | 93.02 | 102.39 | 158.23 | 130.36 | 138 | 173.5 | 16.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -17.02 | +203.06 | -31.94 | +262.64 | -46.48 | -10.5 | +33.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Directors
- Torben Jorgensen NEC (69)
- Fredrik Olsson CEO (50)
- Johny Humaloja CFO (55)
- Linda Andersson VPR (45)
- Helen Nyhlen VPR (57)
- Rolf Lood VRD (37)
- Jonathan Sjoegren VBD (36)
- Susanne Ahlberg GCN (64)
- Mikael Loenn DRC (67)
- Lotta Ljungqvist IND (60)
- Kenth Petersson IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 3rd, 1999
- Public Since
- November 11th, 2005
- No. of Employees
- 32
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm- Shares in Issue
- 66,261,714
- Address
- Medicon Village, Scheelevagen 2, LUND, 223 63
- Web
- https://www.genovis.com/
- Phone
- +46 46101230
- Contact
- Susanne Ahlberg
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for GENO
Q1 2025 Genovis AB Earnings Release
Q2 2025 Genovis AB Earnings Release
Similar to GENO
Acarix AB
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Genovis AB share price?
As of Today at 20:48 UTC, shares in Genovis AB are trading at SEK23.40. This share price information is delayed by 15 minutes.
How has the Genovis AB share price performed this year?
Shares in Genovis AB last closed at SEK23.40 and the price had moved by -9.83% over the past 365 days. In terms of relative price strength the Genovis AB share price has underperformed the FTSE Global All Cap Index by -12.08% over the past year.
What are the analyst and broker recommendations for Genovis AB?
The overall consensus recommendation for Genovis AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genovis AB dividend yield?
Genovis AB does not currently pay a dividend.
Does Genovis AB pay a dividend?
Genovis AB does not currently pay a dividend.
When does Genovis AB next pay dividends?
Genovis AB does not currently pay a dividend.
How do I buy Genovis AB shares?
To buy shares in Genovis AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genovis AB?
As of the previous close price of SEK23.40, shares in Genovis AB had a market capitalisation of SEK1.55bn.
Where are Genovis AB shares listed?
Here are the trading details for Genovis AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: GENO
What kind of share is Genovis AB?
Based on an overall assessment of its quality, value and momentum Genovis AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genovis AB share price forecast for 2025?
The analyst consensus target price for shares in Genovis AB is SEK37.67. That is 60.98% above the last closing price of SEK23.40.
Analysts covering Genovis AB currently have a consensus Earnings Per Share (EPS) forecast of SEK0.45 for the next financial year.
Find out moreWhat is the trend in the Genovis AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genovis AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +6.23%.
As of the last closing price of SEK23.40, shares in Genovis AB were trading -5.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genovis AB PE Ratio?
The Genovis AB PE ratio based on its reported earnings over the past 12 months is 47.02. The shares last closed at SEK23.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genovis AB?
Genovis AB's management team is headed by:
- Torben Jorgensen - NEC
- Fredrik Olsson - CEO
- Johny Humaloja - CFO
- Linda Andersson - VPR
- Helen Nyhlen - VPR
- Rolf Lood - VRD
- Jonathan Sjoegren - VBD
- Susanne Ahlberg - GCN
- Mikael Loenn - DRC
- Lotta Ljungqvist - IND
- Kenth Petersson - IND